神经科

订阅

MedSci主页 / 所有栏目 / 神经科

Alder Bio制药报告了Eptinezumab慢性偏头痛的的新近进展

2018-06-30 MedSci MedSci原创

Eptinezumab慢性偏头痛AlderBio制药
关注

Alder Bio制药（一家专注于开发用于治疗偏头痛的新型治疗性抗体的生物制药公司）于2018年6月29日公布了Eptinezumab的6个月数据。数据显示，在输注300mg Eptinezumab后，患者每月偏头痛日（MMDs）减少了8.8次

偏头痛是一类发作性且常为单侧的搏动性头痛。在美国，偏头痛造成的社会经济负担为10～17亿美元。在我国也有大量患者因偏头痛而影响工作、学习和生活，多数患者有家族史。偏头痛对症治疗可选用非特异性药物治疗，包括简单的止痛药，非甾体类消失药及麻醉药。对于轻、中度头痛，简单的镇痛药及非甾体类消炎药常可缓解头痛的发作。常用的药物有布酚宁、对乙酰氨基酚、阿司匹林、萘普生、吲哚美辛、布洛芬、罗通定等。Alder Bio制药（一家专注于开发用于治疗偏头痛的新型治疗性抗体的生物制药公司）于2018年6月29日公布了Eptinezumab的6个月数据。数据显示，在输注300mg Eptinezumab后，患者每月偏头痛日（MMDs）减少了8.8次。Eptinezumab是Alder领先的针对降钙素基因相关肽（CGRP）预防偏头痛的研究产品候选药物。详细的结果将在今天在加利福尼亚州旧金山举行的第60届AHS年度科学会议上公布。


原始出处：

http://www.firstwordpharma.com/node/1575791#axzz5JsCRXxz0

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780339, encodeId=e3dc1e80339a8, content=<a href='/topic/show?id=f6b73480da' target=_blank style='color:#2F92EE;'>#Bio制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3480, encryptionId=f6b73480da, topicName=Bio制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun May 26 03:26:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918164, encodeId=694b19181646e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 06:26:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985122, encodeId=32541985122b3, content=<a href='/topic/show?id=13eb69000d' target=_blank style='color:#2F92EE;'>#Eptinezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6900, encryptionId=13eb69000d, topicName=Eptinezumab)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Sun Sep 02 10:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912001, encodeId=e9f81912001de, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 30 08:26:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465766, encodeId=e7071465e66b3, content=<a href='/topic/show?id=b164534e540' target=_blank style='color:#2F92EE;'>#慢性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53475, encryptionId=b164534e540, topicName=慢性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ef86754651, createdName=photoman, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469403, encodeId=a44014694030b, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587545, encodeId=6742158e5458f, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2019-05-26 108807375_62823127

    #Bio制药#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1780339, encodeId=e3dc1e80339a8, content=<a href='/topic/show?id=f6b73480da' target=_blank style='color:#2F92EE;'>#Bio制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3480, encryptionId=f6b73480da, topicName=Bio制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun May 26 03:26:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918164, encodeId=694b19181646e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 06:26:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985122, encodeId=32541985122b3, content=<a href='/topic/show?id=13eb69000d' target=_blank style='color:#2F92EE;'>#Eptinezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6900, encryptionId=13eb69000d, topicName=Eptinezumab)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Sun Sep 02 10:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912001, encodeId=e9f81912001de, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 30 08:26:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465766, encodeId=e7071465e66b3, content=<a href='/topic/show?id=b164534e540' target=_blank style='color:#2F92EE;'>#慢性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53475, encryptionId=b164534e540, topicName=慢性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ef86754651, createdName=photoman, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469403, encodeId=a44014694030b, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587545, encodeId=6742158e5458f, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-10-17 sunylz

    #Bio#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1780339, encodeId=e3dc1e80339a8, content=<a href='/topic/show?id=f6b73480da' target=_blank style='color:#2F92EE;'>#Bio制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3480, encryptionId=f6b73480da, topicName=Bio制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun May 26 03:26:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918164, encodeId=694b19181646e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 06:26:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985122, encodeId=32541985122b3, content=<a href='/topic/show?id=13eb69000d' target=_blank style='color:#2F92EE;'>#Eptinezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6900, encryptionId=13eb69000d, topicName=Eptinezumab)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Sun Sep 02 10:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912001, encodeId=e9f81912001de, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 30 08:26:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465766, encodeId=e7071465e66b3, content=<a href='/topic/show?id=b164534e540' target=_blank style='color:#2F92EE;'>#慢性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53475, encryptionId=b164534e540, topicName=慢性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ef86754651, createdName=photoman, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469403, encodeId=a44014694030b, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587545, encodeId=6742158e5458f, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-09-02 ms4964546379600229

    #Eptinezumab#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1780339, encodeId=e3dc1e80339a8, content=<a href='/topic/show?id=f6b73480da' target=_blank style='color:#2F92EE;'>#Bio制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3480, encryptionId=f6b73480da, topicName=Bio制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun May 26 03:26:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918164, encodeId=694b19181646e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 06:26:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985122, encodeId=32541985122b3, content=<a href='/topic/show?id=13eb69000d' target=_blank style='color:#2F92EE;'>#Eptinezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6900, encryptionId=13eb69000d, topicName=Eptinezumab)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Sun Sep 02 10:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912001, encodeId=e9f81912001de, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 30 08:26:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465766, encodeId=e7071465e66b3, content=<a href='/topic/show?id=b164534e540' target=_blank style='color:#2F92EE;'>#慢性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53475, encryptionId=b164534e540, topicName=慢性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ef86754651, createdName=photoman, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469403, encodeId=a44014694030b, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587545, encodeId=6742158e5458f, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-07-30 snf701207

    #mAb#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1780339, encodeId=e3dc1e80339a8, content=<a href='/topic/show?id=f6b73480da' target=_blank style='color:#2F92EE;'>#Bio制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3480, encryptionId=f6b73480da, topicName=Bio制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun May 26 03:26:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918164, encodeId=694b19181646e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 06:26:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985122, encodeId=32541985122b3, content=<a href='/topic/show?id=13eb69000d' target=_blank style='color:#2F92EE;'>#Eptinezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6900, encryptionId=13eb69000d, topicName=Eptinezumab)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Sun Sep 02 10:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912001, encodeId=e9f81912001de, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 30 08:26:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465766, encodeId=e7071465e66b3, content=<a href='/topic/show?id=b164534e540' target=_blank style='color:#2F92EE;'>#慢性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53475, encryptionId=b164534e540, topicName=慢性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ef86754651, createdName=photoman, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469403, encodeId=a44014694030b, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587545, encodeId=6742158e5458f, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-07-02 photoman

    #慢性偏头痛#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1780339, encodeId=e3dc1e80339a8, content=<a href='/topic/show?id=f6b73480da' target=_blank style='color:#2F92EE;'>#Bio制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3480, encryptionId=f6b73480da, topicName=Bio制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun May 26 03:26:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918164, encodeId=694b19181646e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 06:26:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985122, encodeId=32541985122b3, content=<a href='/topic/show?id=13eb69000d' target=_blank style='color:#2F92EE;'>#Eptinezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6900, encryptionId=13eb69000d, topicName=Eptinezumab)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Sun Sep 02 10:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912001, encodeId=e9f81912001de, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 30 08:26:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465766, encodeId=e7071465e66b3, content=<a href='/topic/show?id=b164534e540' target=_blank style='color:#2F92EE;'>#慢性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53475, encryptionId=b164534e540, topicName=慢性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ef86754651, createdName=photoman, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469403, encodeId=a44014694030b, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587545, encodeId=6742158e5458f, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-07-02 zhangjingnwpu

    #ALD#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1780339, encodeId=e3dc1e80339a8, content=<a href='/topic/show?id=f6b73480da' target=_blank style='color:#2F92EE;'>#Bio制药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3480, encryptionId=f6b73480da, topicName=Bio制药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Sun May 26 03:26:00 CST 2019, time=2019-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1918164, encodeId=694b19181646e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Wed Oct 17 06:26:00 CST 2018, time=2018-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1985122, encodeId=32541985122b3, content=<a href='/topic/show?id=13eb69000d' target=_blank style='color:#2F92EE;'>#Eptinezumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6900, encryptionId=13eb69000d, topicName=Eptinezumab)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eq2AGzrugK9ZUjU3eJxzM901ophWib0xJDrSicy49ibWl3zB5pbDto7eoR6tnzwOiaKdbq1a8PcbYFFrw/132, createdBy=6ff22500098, createdName=ms4964546379600229, createdTime=Sun Sep 02 10:26:00 CST 2018, time=2018-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912001, encodeId=e9f81912001de, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Mon Jul 30 08:26:00 CST 2018, time=2018-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465766, encodeId=e7071465e66b3, content=<a href='/topic/show?id=b164534e540' target=_blank style='color:#2F92EE;'>#慢性偏头痛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53475, encryptionId=b164534e540, topicName=慢性偏头痛)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4ef86754651, createdName=photoman, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469403, encodeId=a44014694030b, content=<a href='/topic/show?id=9d6522e613' target=_blank style='color:#2F92EE;'>#ALD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2276, encryptionId=9d6522e613, topicName=ALD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=64f67025397, createdName=zhangjingnwpu, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1587545, encodeId=6742158e5458f, content=<a href='/topic/show?id=a44322e85d' target=_blank style='color:#2F92EE;'>#Alder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2278, encryptionId=a44322e85d, topicName=Alder)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e79417492785, createdName=xuqianhua, createdTime=Mon Jul 02 03:26:00 CST 2018, time=2018-07-02, status=1, ipAttribution=)]
    2018-07-02 xuqianhua

    #Alder#

    0